Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004154 | Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 3 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT00606632 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | completed | Phase 3 | 226 | Heidelberg Pharma AGINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02560584 |
| A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting |
| completed |
| Phase 3 |
| 304 |
| PhotocureINDUSTRY |
| 1 |
| Jul 2, 2018 |
| clinicaltrials |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma(ADAPT) | terminated | Phase 3 | 462 | Argos TherapeuticsINDUSTRY | 8 | Jun 14, 2018 | clinicaltrials |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | withdrawn | Phase 3 | 0 | Medical Enterprises Europe B.V.INDUSTRY | 0 | May 7, 2018 | clinicaltrials |
| NCT03427034 | Assessment of BladderLight SurvEILlance(ABSEIL) | unknown | Phase 2 / Phase 3 | 2,100 | Cambridge University Hospitals NHS Foundation TrustOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | withdrawn | Phase 3 | 0 | Heidelberg Pharma AGINDUSTRY | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 3 | 47 | Spectrum Pharmaceuticals, IncINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT00598806 | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) | completed | Phase 3 | 812 | Spectrum Pharmaceuticals, IncINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 3 | 339 | Immatics Biotechnologies GmbHINDUSTRY | 11 | Oct 12, 2017 | clinicaltrials |
| NCT03296306 | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma(FOCUS) | unknown | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT03193788 | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy(PREMIER) | unknown | Phase 3 | 74 | Asan Medical CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | terminated | Phase 3 | 521 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 8, 2017 | clinicaltrials |
| NCT01613846 | Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | completed | Phase 3 | 544 | Technical University of MunichOTHER | 3 | Apr 20, 2017 | clinicaltrials |
| NCT01064310 | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer(PISCES) | completed | Phase 3 | 169 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 17, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT01099423 | Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer(SURTIME) | unknown | Phase 3 | 99 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Feb 8, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00003126 | Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer | completed | Phase 3 | 69 | Loyola UniversityOTHER | 1 | Jan 4, 2017 | clinicaltrials |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | terminated | Phase 3 | 66 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Dec 13, 2016 | clinicaltrials |
| NCT02951078 | A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer | unknown | Phase 3 | 172 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Genentech, Inc.INDUSTRY | 0 | Oct 19, 2016 | clinicaltrials |
| NCT00028756 | Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium | completed | Phase 3 | 285 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 2, 2016 | clinicaltrials |
| NCT00014534 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 42 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00003623 | High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer | completed | Phase 3 | 21 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
| NCT00072046 | Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) | completed | Phase 3 | 732 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 6, 2016 | clinicaltrials |
| NCT00738530 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | completed | Phase 3 | 649 | Hoffmann-La RocheINDUSTRY | 18 | Jun 23, 2016 | clinicaltrials |
| NCT00729287 | Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer(SELEBLAT) | completed | Phase 3 | 276 | KU LeuvenOTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00974818 | Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients | terminated | Phase 3 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)(Bladder Cancer) | completed | Phase 2 / Phase 3 | 90 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT02030717 | Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma(ASA) | completed | Phase 2 / Phase 3 | 120 | Umeå UniversityOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium(LaMB) | unknown | Phase 2 / Phase 3 | 204 | Queen Mary University of LondonOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00384891 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | terminated | Phase 3 | 190 | Medical Enterprises Europe B.V.INDUSTRY | 4 | Oct 7, 2014 | clinicaltrials |
| NCT01284205 | First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | withdrawn | Phase 3 | 0 | Bioniche Life Sciences Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00002641 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | completed | Phase 3 | 350 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 8, 2014 | clinicaltrials |
| NCT00111020 | Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma | completed | Phase 3 | 2,567 | BayerINDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00002610 | Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors | completed | Phase 3 | 203 | Children's Oncology GroupNETWORK | 7 | Jul 25, 2014 | clinicaltrials |
| NCT00003804 | Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor | unknown | Phase 3 | 350 | University of LeicesterOTHER | 15 | Jun 24, 2014 | clinicaltrials |
| NCT00047138 | Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor | unknown | Phase 3 | 350 | University of LeicesterOTHER | 4 | Jun 24, 2014 | clinicaltrials |
| NCT00732914 | Sequential Study to Treat Renal Cell Carcinoma | completed | Phase 3 | 272 | Sponsor GmbHOTHER | 1 | Apr 23, 2014 | clinicaltrials |
| NCT00586105 | Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) | completed | Phase 3 | 39 | BayerINDUSTRY | 2 | Apr 16, 2014 | clinicaltrials |
| NCT02074189 | Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer | unknown | Phase 3 | 200 | Southwest Hospital, ChinaOTHER | 1 | Feb 28, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Nov 8, 2018source: clinicaltrials